Effect of Maternal Pharmacotherapy on Foetal Development
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.author | Adewuyi , Michael Adeniyi | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | |
| dc.contributor.opponent | Szentmiklósi, József | |
| dc.contributor.opponent | Halasi, Barbara Dóra | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.opponentdept | Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet | |
| dc.date.accessioned | 2026-04-14T07:33:27Z | |
| dc.date.available | 2026-04-14T07:33:27Z | |
| dc.date.created | 2026-03-18 | |
| dc.description.abstract | This thesis explores the complex tri-compartmental pharmacological interaction between the mother, the placenta, and the foetus. I argue that maternal physiological changes, such as a 50% increase in blood volume and doubled renal clearance, significantly alter drug concentrations and can lead to sub-therapeutic treatment. The placenta is presented not as a passive barrier, but as an active biochemical gatekeeper that regulates drug exposure through enzymes and efflux transporters. Central to my research is the "chronological imperative," which asserts that the timing of drug exposure—particularly during the critical window of organogenesis—is the primary determinant of structural or functional harm. I examine specific high-risk scenarios, such as the Potter sequence caused by ACE inhibitors, which illustrates how late-term exposure can lead to foetal renal failure and developmental compression. My findings highlight that maternal stability is the essential precondition for foetal safety, as untreated conditions often pose a greater risk than the medications themselves. Ultimately, I advocate for a shift toward precision medicine using advanced technologies like PBPK modelling and "placenta-on-a-chip" to replace trial-and-error prescribing with evidence-based care. | |
| dc.description.course | általános orvos | |
| dc.description.courselang | angol | |
| dc.description.coursespec | Orvosbiológia-farmakológia | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 49 pages | |
| dc.identifier.uri | https://hdl.handle.net/2437/406191 | |
| dc.language.iso | en | |
| dc.rights.info | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Maternal-Foetal Pharmacology | |
| dc.subject | Teratogenicity | |
| dc.subject | Placental Transfer | |
| dc.subject.dspace | Medicine | |
| dc.title | Effect of Maternal Pharmacotherapy on Foetal Development |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- RECORRECTED THESIS.pdf
- Méret:
- 1.23 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
Engedélyek köteg
1 - 1 (Összesen 1)
Nincs kép
- Név:
- license.txt
- Méret:
- 1.94 KB
- Formátum:
- Item-specific license agreed upon to submission
- Leírás: